Kate E Lines

1.2k total citations
41 papers, 609 citations indexed

About

Kate E Lines is a scholar working on Epidemiology, Molecular Biology and Oncology. According to data from OpenAlex, Kate E Lines has authored 41 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 15 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Kate E Lines's work include Neuroendocrine Tumor Research Advances (23 papers), Neuroblastoma Research and Treatments (13 papers) and Lung Cancer Research Studies (10 papers). Kate E Lines is often cited by papers focused on Neuroendocrine Tumor Research Advances (23 papers), Neuroblastoma Research and Treatments (13 papers) and Lung Cancer Research Studies (10 papers). Kate E Lines collaborates with scholars based in United Kingdom, United States and Netherlands. Kate E Lines's co-authors include Rajesh V. Thakker, Mark Stevenson, Gerlof D. Valk, Nancy D. Perrier, Maria Luisa Brandi, Sunita Agarwal, Morten Frost, Tatjana Crnogorac‐Jurcevic, Claude Chelala and Gerard Walls and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Endocrine Reviews.

In The Last Decade

Kate E Lines

40 papers receiving 607 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kate E Lines United Kingdom 15 315 267 195 175 112 41 609
Sara Molatore Italy 12 132 0.4× 221 0.8× 76 0.4× 226 1.3× 65 0.6× 16 537
Lucie Coppin France 14 94 0.3× 140 0.5× 49 0.3× 177 1.0× 55 0.5× 25 421
Rita Domingues Portugal 14 156 0.5× 200 0.7× 44 0.2× 156 0.9× 352 3.1× 30 573
Shinsuke Uraki Japan 12 99 0.3× 138 0.5× 59 0.3× 104 0.6× 160 1.4× 33 441
G. F. W. Scheumann Germany 11 126 0.4× 152 0.6× 40 0.2× 205 1.2× 285 2.5× 25 591
Nikolaos Givalos Greece 12 78 0.2× 321 1.2× 68 0.3× 224 1.3× 33 0.3× 13 678
S. Hescot France 15 68 0.2× 191 0.7× 46 0.2× 54 0.3× 233 2.1× 48 604
Paul Waring Australia 7 100 0.3× 171 0.6× 67 0.3× 177 1.0× 51 0.5× 10 427
Vipul T. Lakhani United States 9 184 0.6× 192 0.7× 119 0.6× 86 0.5× 111 1.0× 11 425
Claire Coire Canada 13 91 0.3× 72 0.3× 40 0.2× 58 0.3× 216 1.9× 18 415

Countries citing papers authored by Kate E Lines

Since Specialization
Citations

This map shows the geographic impact of Kate E Lines's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate E Lines with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate E Lines more than expected).

Fields of papers citing papers by Kate E Lines

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate E Lines. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate E Lines. The network helps show where Kate E Lines may publish in the future.

Co-authorship network of co-authors of Kate E Lines

This figure shows the co-authorship network connecting the top 25 collaborators of Kate E Lines. A scholar is included among the top collaborators of Kate E Lines based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate E Lines. Kate E Lines is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hannan, Fadil, Kreepa Kooblall, Mark Stevenson, et al.. (2025). Characterization of quinazolinone calcilytic therapy for autosomal dominant hypocalcemia type 1 (ADH1). Journal of Biological Chemistry. 301(4). 108404–108404.
2.
Brandi, Maria Luisa, Carolina R C Pieterman, Kate E Lines, et al.. (2025). Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. The Lancet Diabetes & Endocrinology. 13(8). 699–721. 4 indexed citations
3.
Pieterman, Carolina R C, Francesca Marini, Kate E Lines, et al.. (2025). Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis. The Lancet Diabetes & Endocrinology. 13(8). 685–698. 6 indexed citations
4.
Metzcar, John, et al.. (2025). Improving neuroendocrine tumor treatments with mathematical modeling: lessons from other endocrine cancers. PubMed. 5(1). e240025–e240025. 1 indexed citations
5.
Kooblall, Kreepa, Mark Stevenson, Raphael Heilig, et al.. (2024). Identification of cellular retinoic acid binding protein 2 (CRABP2) as downstream target of nuclear factor I/X (NFIX): implications for skeletal dysplasia syndromes. JBMR Plus. 8(7). ziae060–ziae060. 1 indexed citations
6.
Zecchin, Davide, Nicole Knöpfel, Mark Stevenson, et al.. (2023). GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics. Journal of Investigative Dermatology. 144(4). 811–819.e4. 7 indexed citations
7.
Srivastava, Kirtiman, et al.. (2023). S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer. Oncogene. 42(46). 3422–3434. 4 indexed citations
8.
Thakker, Rajesh V., et al.. (2023). The role of DNA methylation in human pancreatic neuroendocrine tumours. SHILAP Revista de lepidopterología. 3(1). e230003–e230003. 3 indexed citations
9.
Kumar, Suresh, Po Hien Ear, Kate E Lines, et al.. (2022). Preclinical Models of Neuroendocrine Neoplasia. Cancers. 14(22). 5646–5646. 6 indexed citations
10.
Brandi, Maria Luisa, Sunita Agarwal, Nancy D. Perrier, et al.. (2020). Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocrine Reviews. 42(2). 133–170. 112 indexed citations
11.
Lines, Kate E, Lisa B. Nachtigall, Laura E. Dichtel, et al.. (2019). MON-335 Phenocopy of Multiple Endocrine Neoplasia Type 1 (MEN1) Due to a Germline Cell Division Cycle 73 (CDC73) Variant. Journal of the Endocrine Society. 3(Supplement_1). 1 indexed citations
12.
Stevenson, Mark, Kate E Lines, & Rajesh V. Thakker. (2018). Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America. 47(3). 525–548. 14 indexed citations
13.
Frost, Morten, Kate E Lines, & Rajesh V. Thakker. (2018). Current and emerging therapies for PNETs in patients with or without MEN1. Nature Reviews Endocrinology. 14(4). 216–227. 47 indexed citations
14.
Gorvin, Caroline M., Paul Newey, Angela Rogers, et al.. (2018). Association of prolactin receptor (PRLR) variants with prolactinomas. Human Molecular Genetics. 28(6). 1023–1037. 26 indexed citations
15.
Lines, Kate E, Mark Stevenson, P. Filippakopoulos, et al.. (2017). Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors. Oncogenesis. 6(5). e332–e332. 39 indexed citations
16.
Walls, Gerard, Mark Stevenson, Kate E Lines, et al.. (2017). Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome. Oncogene. 36(28). 4025–4036. 28 indexed citations
17.
Lines, Kate E, Mark Stevenson, & Rajesh V. Thakker. (2015). Animal models of pituitary neoplasia. Molecular and Cellular Endocrinology. 421. 68–81. 16 indexed citations
18.
Yates, Christopher J., Kate E Lines, & Rajesh V. Thakker. (2014). Molecular genetic advances in pituitary tumor development. Expert Review of Endocrinology & Metabolism. 10(1). 35–53. 6 indexed citations
19.
Lines, Kate E, Claude Chelala, Branko Dmitrović, et al.. (2012). S100P-Binding Protein, S100PBP, Mediates Adhesion through Regulation of Cathepsin Z in Pancreatic Cancer Cells. American Journal Of Pathology. 180(4). 1485–1494. 32 indexed citations
20.
Barry, Sayka, Claude Chelala, Kate E Lines, et al.. (2012). S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. Clinical & Experimental Metastasis. 30(3). 251–264. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Molatore Breakdown of academic impact, for papers by Lucie Coppin Breakdown of academic impact, for papers by Rita Domingues Breakdown of academic impact, for papers by Shinsuke Uraki Breakdown of academic impact, for papers by G. F. W. Scheumann Breakdown of academic impact, for papers by Nikolaos Givalos Breakdown of academic impact, for papers by S. Hescot Breakdown of academic impact, for papers by Paul Waring Breakdown of academic impact, for papers by Vipul T. Lakhani Breakdown of academic impact, for papers by Claire Coire
Rankless by CCL
2026